CorMedix Inc. Common Stock
Financials
Valuation Metrics
CorMedix Inc. Common Stock's Market Cap is $447M. At end of 2025 it was $838M. Ranked #2780 of 3,118 in US market (top 89%), #1220 of 1,474 on NASDAQ (top 83%), #220 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 83%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $447M | US#2,780/3,118 Sec#220/265 |
| Revenue | $462M | US#2,267/3,118 Sec#77/265 |
| Net Income | $187M | US#1,315/3,118 Sec#43/265 |
| Total Assets | $904M | US#2,517/3,118 Sec#110/265 |
| Net Assets | $461M | US#2,276/3,118 Sec#116/265 |
| Employees | 191 | US#2,487/3,118 Sec#130/265 |
| Value | ||
| P/E | 2.39x | US#15/3,118 Sec#1/265 |
| P/B | 0.97x | US#379/3,118 Sec#22/265 |
| PEG | 0.01x | US#28/3,118 Sec#3/265 |
| P/S | 0.97x | US#693/3,118 Sec#11/265 |
| EV/EBITDA | 1.34x | US#12/3,118 Sec#2/265 |
| FCF Yield | 56.34% | US#27/3,118 Sec#1/265 |
| Profitability | ||
| ROE | 40.62% | US#165/3,118 Sec#14/265 |
| ROA | 20.70% | US#102/3,118 Sec#16/265 |
| Op. Margin | 46.95% | US#156/3,118 Sec#9/265 |
| Revenue Growth | 280.50% | US#43/3,118 Sec#18/265 |
| Earnings Growth | 265.86% | US#131/3,118 Sec#6/265 |
| Financial Health | ||
| Debt Ratio | 96.18% | US#1,055/3,118 Sec#161/265 |
| Total Debt | $145M | US#2,330/3,118 Sec#104/265 |
| FCF | $252M | US#1,259/3,118 Sec#43/265 |
| Cash | $257M | US#1,539/3,118 Sec#94/265 |
| Current Ratio | 2.56x | US#931/3,118 Sec#199/265 |
| Net Debt/EBITDA | -0.45x | US#416/3,118 Sec#24/265 |
| Performance | ||
| 1Y Return | -50.99% | US#2,878/3,118 Sec#236/265 |
| 1M Return | -26.04% | US#2,929/3,118 Sec#240/265 |
| From 52W High | -56.26% | US#2,761/3,118 Sec#216/265 |
| 1Y MDD | -55.26% | US#2,589/3,118 Sec#187/265 |
| Trading | ||
| Volume | 6,709,040 shares | US#295/3,118 Sec#18/265 |
| Trading Value | $42M | US#1,426/3,118 Sec#93/265 |
| Per Share | ||
| EPS | $2.39 | US#1,222/3,118 Sec#35/265 |
| BPS | $5.87 | US#2,202/3,118 Sec#114/265 |
Company Info
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.